Skip to main content Skip to main content
Not investment advice. Educational platform. See Disclaimer.
NASDAQ: VTRS

Viatris Inc.

Healthcare | Drug Manufacturers - Specialty & Generic
$16.70 +1.66 (+11.01%) as of 2026-07-14 20:11 UTC
Market Cap$19.4B
Volume8.61M
EPS (TTM)$-3.00

Viatris Inc. (NASDAQ: VTRS) is a $19.4B drug manufacturers - specialty & generic company trading at $16.70 (+11.0% today). Figures from SEC EDGAR and market feeds; updated 2026-07-14 20:11 UTC.

52-Week Range
Low $13.37High $16.74

What Viatris Inc. does

Viatris is a global healthcare company that supplies medicines to approximately one billion patients annually across more than 165 countries and territories. The company operates a diverse portfolio consisting of generic drugs, established brand-name medicines, and innovative pharmaceutical products, supported by more than 1,400 approved molecules and 27 manufacturing and distribution sites worldwide.

Summarized from Viatris Inc.’s SEC filings · Read the filing ↗

Pre-revenue, development-stage company: standard profitability ratios (P/E, EV/EBITDA, ROE) do not apply yet because there are no earnings. Watch cash, cash runway, net loss, R&D spend and share dilution instead.
Key facts
Quote
Price$16.70
Change (1D)+1.66 (+11.01%)
Market cap$19.4B
Volume8.61M shares
52-week range$13.37 – $16.74
Valuation
EPS (TTM)$-3.00
Price/book1.32×
Debt/equity0.98
Returns
52-week return+24.9%
Revenue, margins & earnings
FY2021: net loss $1.27B on revenue $17.9B$17.9BFY2021FY2022 Revenue: $16.3B — margin split not shown (non-operating gains)$16.3BFY2022FY2023 Taxes & interest: $712MFY2023 Operating expenses: $5.67BFY2023 Cost of revenue: $8.99B$15.4BFY2023FY2024: net loss $634M on revenue $14.7B$14.7BFY2024FY2025: net loss $3.51B on revenue $14.3B$14.3BFY2025
  • Net income
  • Taxes & interest
  • Operating expenses
  • Cost of revenue
  • Net loss year
Annual revenue; bands show net, operating, gross margins · Open in Platform →
SEC Filings SEC EDGAR ↗
Recent Insider Activity (last 90 days)
Source: SEC EDGAR · Filed 2026-07-01
  • 2026-07-01Groothuis Leo FransA2,756$43.8K
  • 2026-07-01SIMMONS DAVID SA2,362$37.5K
  • 2026-06-26Campbell PaulSee RemarksSELL-50,076$809.8K
Sign in to see all transactions →
Top Institutional Holders (latest 13F)
Source: SEC EDGAR · As of 2026-Q1
  • VANGUARD GROUP INC136,667,246$1.70B-2.6%
  • DAVIS SELECTED ADVISERS78,211,191$1.06B+0.0%
  • VANGUARD CAPITAL MANAGEMENT LLC74,716,631$1.01BNEW
View QoQ ownership changes →
Company news View all →
Questions this page answers

What does Viatris Inc. do?

Viatris is a global healthcare company that supplies medicines to approximately one billion patients annually across more than 165 countries and territories.

What is VTRS's valuation?

VTRS trades at $16.70, as of 2026-07-14.

When did VTRS last file with the SEC?

Viatris Inc.'s most recent SEC filing on record is a 8-K filed 2026-07-01. All filings link to their SEC EDGAR originals above.

Where does this data come from?

SEC EDGAR filings and public market data feeds, fetched 2026-07-14 20:11 UTC. This page is also available as JSON at /api/data?ticker=VTRS and is emitted with FAQPage structured data for machine reading.

For you

Charts, 10-year financials, peer comparison, screening and portfolio tracking for VTRS and 3,500+ tickers.

Create a free account — keep VTRS
For your agent
GET /api/data?ticker=VTRS

This page as JSON via rel="alternate" · REST API docs · MCP server (51 tools) · llms.txt